Fourth Quarter 2024 Earnings

revvity

January 31, 2025

Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Financial Information” section of our website at www.revvity.com.

Key Takeaways

Innovation	Transformation	Performance
New partnerships with Genomics England and Element Biosciences Launched new FDA cleared assay for Free Testosterone in US	Announced new operational & financial segmentation beginning in FY25 Investor Day held in San Diego	Stronger organic growth driven by Life Sciences Reagents & Software Strong synergy realization & Cash flow generation

A Scientific Solutions Company Helping To Solve The World's Greatest Health Challenges From Discovery To Development, and Diagnosis to Cure

4Q24 Revenue Highlights

Segments

Diagnostics · Life Sciences



Geographic

AMERICAS · APAC · EU



Product Mix

RECURRING · NON-RECURRING



Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

2024 Revenue Highlights

Segments

Diagnostics Life Sciences



Geographic

AMERICAS APAC EU



Product Mix

RECURRING NON-RECURRING



4Q24 Financial Results

ADJUSTED REVENUE	ADJUSTED OP MARGIN	ADJUSTED EPS	FREE CASH FLOW
$730M	**30.3%**	**$1.42**	**$151M**
⬆ +5% y/y	⬆ +280bps y/y	⬆ +14% y/y	$578M FY24
Organic: +6% | M&A: 0% | FX: -1%	Adj. Gross Margin: 61.4% | +120bps y/y	Adj. Tax Rate: 15.7%	FY24 FCF % Adj. NI 96%
		Adj. Net Interest & Other: $17M	Excludes AES inflows of an additional $157M YTD

Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

2024 Financial Results

ADJUSTED REVENUE	ADJUSTED OP MARGIN	ADJUSTED EPS	FREE CASH FLOW
$2,756M	**28.3%**	**$4.90**	**$578M**
⬆ +0% y/y	⬆ +30bps y/y	⬆ +6% y/y	FCF % Adj. NI 96%
Organic: +1% | M&A: 0% | FX: 0%	Adj. Gross Margin: 61.3% | -10bps y/y	Adj. Tax Rate: 18.4%	Excludes AES inflows of an additional $157M YTD
		Adj. Net Interest & Other: $43M	

revvity

Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

Life Sciences

Product



REVENUE	AJUSTED OP MARGINS
5% Organic Growth	38.9%
Reported: 5% | M&A: 0% | FX: 0%	+200bps y/y

- +MSD growth from Pharma/Biotech, +LSD growth from Academic/Gov’t
- +MSD growth in reagents; -HSD instruments decline
- +DD software growth driven by new orders and strong SaaS performance
- Solid margin expansion yr/yr driven by mix and synergies, partially offset by investments

Diagnostics

End Market



REVENUE	AJUSTED OP MARGINS
6% Organic Growth	25.0%
Reported: 4% | M&A: 0% | FX: -1%	+390 bps y/y

- +MSD ImmunoDX globally and in China
- +HSD Reproductive Health globally; +MSD in China
- +LSD Applied Genomics reflects positive quarterly growth for first time since 3Q22
- Margin expansion driven by commercial and operational synergies

2025 Financial Guidance

REVENUE	**$2.80B - $2.85B**
	Reported: 1.5% to 3.5%
	Organic: 3% to 5%
	FX: -1.5%, M&A: 0%
ADJUSTED OP. MARGIN	**28.5-28.7%**
ADJUSTED EPS	**$4.90 - $5.00**
	Adj. Net interest expense, other: ~$70M
	Adjusted tax rate: ~20%
	Average diluted share count: 120.0M

Revvity.com